Consort Medical plc, a leading player in the pharmaceutical and medical device industry, is headquartered in Great Britain. Founded in 1984, the company has established itself as a key innovator in drug delivery systems and medical devices, serving a global market with a strong presence in Europe and North America. Specialising in the development of advanced inhalation devices and other drug delivery technologies, Consort Medical is renowned for its commitment to quality and innovation. Their core products, including the Bespak and Aesica brands, are designed to enhance patient outcomes through precision and reliability. With a robust market position, Consort Medical has achieved significant milestones, including strategic partnerships and a focus on sustainability, solidifying its reputation as a trusted partner in the healthcare sector.
How does Consort Medical plc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Consort Medical plc's score of 21 is lower than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Consort Medical plc, headquartered in Great Britain, currently does not have specific carbon emissions data available for recent years, as indicated by the absence of reported figures. The company is identified as a current subsidiary and has not disclosed any reduction targets or climate pledges. As a subsidiary, Consort Medical plc may inherit climate-related data and commitments from its parent organization, but specific details regarding these cascaded emissions or targets are not provided. The lack of emissions data and defined climate initiatives suggests that the company may still be in the early stages of developing its sustainability strategy. In the context of the industry, it is essential for companies like Consort Medical plc to establish clear carbon reduction targets and commitments to align with global climate goals. Without specific emissions data or reduction initiatives, the company faces challenges in demonstrating its commitment to sustainability and addressing climate change effectively.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Consort Medical plc has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
